Collaboration and license agreements - Summarizes the deferred revenue amounts allocated to performance obligations (Details) - USD ($) $ in Thousands |
Sep. 30, 2026 |
Dec. 31, 2025 |
|---|---|---|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
| Total Roche Agreement deferred revenue | $ 102,261 | $ 111,332 |
| Roche Agreement [Member] | ||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
| Total Roche Agreement deferred revenue | 13,162 | 22,657 |
| Roche Agreement [Member] | Research and Development of Intial Targets [Member] | ||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
| Total Roche Agreement deferred revenue | 6,248 | 14,140 |
| Roche Agreement [Member] | Research and Development for Replacement Targets [Member] | ||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
| Total Roche Agreement deferred revenue | $ 6,914 | $ 8,517 |